IRD Opus Genetics, Inc.
Company Analysis
Latest News
🔴 Opus Genetics is trading 5% down — reason remains unclear
Opus Genetics is trading at $4.58, down 5.27%, with no clear company-specific explanation identified for the decline on October 1, 2026. - The company’s...
🟢 Opus Genetics is trading 5% up
Opus Genetics is trading 5.35% higher at $5.22, compared with its September 29 close of $4.96; no clear company-specific catalyst has been identified. - The...
🟢 Opus Genetics is trading 5.73% up in pre-market — no clear catalyst identified
Opus Genetics is trading 5.73% up in pre-market at $5.24, versus the September 29 close of $4.96; no clear company-specific catalyst for the September 30 move...
🟢 Opus Genetics is trading 6.13% up in pre-market
Opus Genetics is trading 6.13% higher in pre-market at $5.36, versus the September 28 close of $5.05; no clear catalyst has been identified. - The provided...
🟢 Opus Genetics is trading 5% up with no clear catalyst identified
Opus Genetics is trading at $5.02, up +5.46%, with no specific driver identified. - No verified September 28 company announcement directly explains the gain;...
🔴 Opus Genetics is trading 5.4% down today as crude and Treasury yields pressure growth stocks
Opus Genetics is trading 5.4% lower at $4.88 as weaker risk sentiment across U.S. equities weighs on shares. - The Nasdaq Composite is down 1.00%; higher...
🟢 Opus Genetics is trading 5% up today as broader markets rise
Opus Genetics is trading at $5.46 (+5.31%) as broader markets strengthen. - The S&P 500 is up 0.90%, while the Nasdaq is up 1.43%. - Falling oil prices, lower...
🔴 Opus Genetics is trading 5.7% down today as biotech sentiment weakens
Opus Genetics is trading 5.7% down at $5.49 on September 16, 2026, as biotech sentiment weakens in the absence of a new company-specific announcement. - The...
🟢 Opus Genetics is trading 6.3% up today after corrected OPGx-BEST1 data supported Phase 3
Opus Genetics is trading at $6.45, up +6.29% after correcting an immaterial visual-acuity calculation error in OPGx-BEST1 Cohort 1 data. - The revised...
Opus Genetics Corrects and Reissues Positive OPGx-BEST1 Phase 1/2 Clinical Data
Opus Genetics (IRD) filed a revised investor presentation to correct a self-described "immaterial error" in its previously announced clinical data for the...
🟢 Opus Genetics is trading 5.58% up today after positive low-dose BIRD-1 results
Opus Genetics is trading at $6.05, up 5.58% after positive low-dose Cohort 1 results from the Phase 1/2 BIRD-1 trial. - The stock is extending its September 9...
🟢 Opus Genetics is trading 7.33% up in after-hours trading after positive BIRD-1 Cohort 1 results
Opus Genetics is trading 7.33% up at $6.15 in after-hours trading after reporting positive low-dose Cohort 1 results from its Phase 1/2 BIRD-1 trial. • All...
Opus Genetics' Gene Therapy Trial Hits Every Mark — But Can a Five-Patient Study Justify a $566 Million Valuation?
Shares of Opus Genetics (Nasdaq: IRD) surged 57% to $6.81 in active morning trading after the company reported that all five patients in the first cohort of...
🟢 Opus Genetics is trading 60% up today after positive low-dose Cohort 1 BIRD-1 results
Opus Genetics is trading 59.91% up now at $6.81 after positive low-dose Cohort 1 results from its BIRD-1 Phase 1/2 trial. - All five participants showed...
🟢 Opus Genetics is trading 10.14% up in pre-market after all five low-dose participants reportedly improved vision
Opus Genetics is trading 10.14% up now at $4.78 after positive interim Phase 1/2 BIRD-1 data for OPGx-BEST1. - All five low-dose cohort participants...
🟢 Opus Genetics is trading 8.8% up in pre-market today after positive interim BIRD-1 data
Opus Genetics is trading 8.8% up in pre-market today at $4.72 after reporting positive interim Phase 1/2 BIRD-1 data for OPGx-BEST1. - All five participants...
Opus Genetics Reports Positive Phase 1/2 Data for OPGx-BEST1 Gene Therapy
Opus Genetics announced positive interim data from the low-dose cohort of its Phase 1/2 clinical trial (BIRD-1) for OPGx-BEST1, a gene therapy for inherited...
🔴 Opus Genetics is trading 5.05% down today ahead of September 9 OPGx-BEST1 Cohort 1 data
Opus Genetics is trading at $4.43, down 5.05%, after no clear negative company-specific announcement was identified for September 8, 2026. - Investors are...
BlackRock Buys $12.8 Million Opus Genetics Stake, Leading Institutional Investment
BlackRock Inc. acquired 3,116,487 shares of Opus Genetics for approximately $12.81 million. This investment establishes a 3.77% ownership stake in the company....
🟢 Opus Genetics is trading 6.7% up today ahead of September 9 Cohort 1 data webcast
Opus Genetics is trading at $4.75 (+6.72%) after its September 2 announcement of a September 9 webcast presenting topline Cohort 1 data from the Phase 1/2...